🔗 Share this article

While the United States continues making sweeping adjustments to its vaccination recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on coronavirus shots during the pandemic and has concentrated on potential deaths after Covid vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Health officials had intended to announce radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US at odds with a large portion of the international standard with little proof for improved outcomes. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Høeg is listed to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A New Direction at the Agency

This interim role could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon rolling back already-approved vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US so as to align more in line with Denmark, a nation with universal health coverage and a population about the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Background

The appointee has no obvious track record in pharmaceutical research, oversight or leadership, which has been typical for former heads of the CBER. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a major agency. She has no expertise in drug approvals.”

Former directors of the center would “understand legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she lacks the type of experience that prior appointees who headed the center have had.”

CDER has an immense portfolio at the agency, Woodcock pointed out.

“The public just zeroes in on the innovative therapies, but the generic program clears a multitude of generic medications. There’s a biosimilars division, over-the-counter program and more, and each of these must be managed,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management element to the job, which supervises more than 5,000 personnel. “It’s a huge administrative position, if you do it right,” Woodcock added.

Agency Reaction and Controversial Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among regulatory chiefs on immunizations, a representative stated that the “concerns rely on incorrect assumptions”.

“Her experience is consistent with the duties of her role,” the spokesperson said, citing the period Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed expedited therapy clearance system that apparently troubled her former heads. “How are these therapies being picked for this fast-track system? Who takes the calls?” Dr. Howard asked. “There’s a lot of secrecy happening at the agency right now.”

Overall, he stated, “the FDA appears to be shifting towards less stringent oversight of most medications, except for immunizations.”

Public Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, past, some experts observe. She published a study using unverified crowd-sourced reports to estimate the rate of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the new administration included revising rules for new vaccines and halting “optional” immunizations, she said following the vote on a audio program. At the FDA, Høeg has allegedly proposed preventing teenage boys from receiving COVID-19 vaccines.

“She is an all-around ideologue who commences with her preconceived notions and tailors the evidence to accommodate the data in a highly disingenuous, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|